193 related articles for article (PubMed ID: 36786158)
1. Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
Yanase T; Tsuruta N; Yamaguchi K; Ohata C; Ohyama B; Katayama E; Sugita K; Kuwashiro M; Hashimoto A; Yonekura K; Higashi Y; Murota H; Koike Y; Matsuzaka Y; Kikuchi S; Hatano Y; Saito K; Takahashi K; Miyagi T; Kaneko S; Ota M; Harada K; Morizane S; Ikeda K; Furue M; Nakahara T; Okazaki F; Sasaki N; Okada E; Yoshida Y; Ito K; Imafuku S
J Dermatol; 2023 Jun; 50(6):753-765. PubMed ID: 36786158
[TBL] [Abstract][Full Text] [Related]
2. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
[TBL] [Abstract][Full Text] [Related]
3. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry.
Bayaraa B; Imafuku S
J Dermatol; 2019 May; 46(5):389-398. PubMed ID: 30861182
[TBL] [Abstract][Full Text] [Related]
4. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
5. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan.
Kishimoto M; Komine M; Kamiya K; Sugai J; Mieno M; Ohtsuki M
J Dermatol; 2020 Jan; 47(1):33-40. PubMed ID: 31696543
[TBL] [Abstract][Full Text] [Related]
6. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
Mease PJ; Armstrong AW
Drugs; 2014 Mar; 74(4):423-41. PubMed ID: 24566842
[TBL] [Abstract][Full Text] [Related]
7. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
8. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
9. Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic Arthritis.
Jin Y; Lee H; Lee MP; Landon JE; Merola JF; Desai RJ; Kim SC
Arthritis Care Res (Hoboken); 2022 Nov; 74(11):1792-1805. PubMed ID: 33973371
[TBL] [Abstract][Full Text] [Related]
10. Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study.
Kishimoto M; Komine M; Kamiya K; Sugai J; Kuwahara A; Mieno M; Ohtsuki M
Dermatol Ther (Heidelb); 2023 Jun; 13(6):1347-1360. PubMed ID: 37204609
[TBL] [Abstract][Full Text] [Related]
11. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation.
Chat VS; Ellebrecht CT; Kingston P; Gondo G; Bell S; Cordoro KM; Desai SR; Duffin KC; Feldman SR; Garg A; Gelfand JM; Gladman D; Green LJ; Gudjonsson J; Han G; Hawkes JE; Kircik L; Koo J; Langley R; Lebwohl M; Michael Lewitt G; Liao W; Martin G; Orbai AM; Reddy SM; Richardson V; Ritchlin CT; Schwartzman S; Siegel EL; Van Voorhees AS; Wallace EB; Weinberg JM; Winthrop KL; Yamauchi P; Armstrong AW
J Am Acad Dermatol; 2024 Jun; 90(6):1170-1181. PubMed ID: 38331098
[TBL] [Abstract][Full Text] [Related]
12. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Yeung J; Carrascosa JM; Piaserico S; Gisondi P; Lynde C; Ferreira P; Bastos PM; Dauden E; Leite L; Valerio J; Del Alcázar-Viladomiu E; Rull EV; Llamas-Velasco M; Pirro F; Messina F; Bruni M; Licata G; Ricceri F; Nidegger A; Hugo J; Mufti A; Daponte AI; Teixeira L; Balato A; Romanelli M; Prignano F; Gkalpakiotis S; Conrad C; Lazaridou E; Rompoti N; Papoutsaki M; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2022 Nov; 23(6):891-904. PubMed ID: 35976568
[TBL] [Abstract][Full Text] [Related]
13. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis.
Lunder T; Zorko MS; Kolar NK; Suhodolcan AB; Marovt M; Leskovec NK; Marko PB
Int J Dermatol; 2019 Jun; 58(6):631-641. PubMed ID: 30973647
[TBL] [Abstract][Full Text] [Related]
14. A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan.
Ohata C; Ohyama B; Nanri A; Shintani T; Nakama T
J Dermatolog Treat; 2019 Feb; 30(1):45-48. PubMed ID: 29676591
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study.
Wang C; Torisu-Itakura H; Hanada T; Matsuo T; Cai Z; Osaga S; Aranishi T
J Dermatolog Treat; 2023 Dec; 34(1):2229465. PubMed ID: 37403477
[TBL] [Abstract][Full Text] [Related]
17. Japanese guidance for use of biologics for psoriasis (the 2019 version).
Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
[TBL] [Abstract][Full Text] [Related]
18. Establishment of the Western Japan Psoriasis Registry and first cross-sectional analysis of registered patients.
Tsuruta N; Imafuku S;
J Dermatol; 2021 Nov; 48(11):1709-1718. PubMed ID: 34427347
[TBL] [Abstract][Full Text] [Related]
19. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
20. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.
Graier T; Salmhofer W; Jonak C; Weger W; Kölli C; Gruber B; Sator PG; Prillinger K; Mlynek A; Schütz-Bergmayr M; Richter L; Ratzinger G; Painsi C; Selhofer S; Häring N; Wippel-Slupetzky K; Skvara H; Trattner H; Tanew A; Inzinger M; Tatarski R; Bangert C; Ellersdorfer C; Lichem R; Gruber-Wackernagel A; Hofer A; Legat F; Schmiedberger E; Strohal R; Lange-Asschenfeldt B; Schmuth M; Vujic I; Hoetzenecker W; Trautinger F; Saxinger W; Müllegger R; Quehenberger F; Wolf P
Br J Dermatol; 2021 Jun; 184(6):1094-1105. PubMed ID: 33289075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
